Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 11:15 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 2,516 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Sequence Clear all

Conditions: Healthy
Interventions: K-877 CR Tablet A, K-877 CR Tablet B, K-877 CR Tablet E, K-877 IR Tablet; Drug
Lead sponsor: Kowa Research Institute, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Tai Chi, Exercise; Behavioral
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 23 Years
Enrollment: 145 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Infertility, Male, Gene Abnormality, Sterility, Male
Interventions: Stem cell, Genetic Screening, Genetic Reprogramming, Cell Maturation; Genetic
Lead sponsor: CellARTs Inc.; Industry
Eligibility: 18 Years to 60 Years · Male only
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Alzheimer's Disease, Huntington's Disease
Interventions: Dimebon alone, Dimebon + Ketoconazole, Dimebon + Omeprazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Kalamazoo, Michigan

Conditions: Pregnancy Related, Postpartum, Pain
Interventions: BELIEVE IPE Training, Usual Care; Behavioral · Other
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years to 99 Years
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Liver Fibrosis, Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Interventions: Dietary Supplement/Behavioral: Navy Bean-Rich Diet, Habitual Diet (Control); Other
Lead sponsor: Icahn School of Medicine at Mount Sinai; Other
Eligibility: 18 Years to 75 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy
Interventions: Duragesic (Fentanyl Transdermal System [TDS] Small Patches), New JNJ-35685-AAA-G016 (Fentanyl TDS -Small Patches), Aged JNJ-35685-AAA-G016 (Fentanyl TDS Small Patches), Duragesic (Fentanyl TDS Large Patches), New JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches), Aged JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches); Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Cypress, California

Conditions: Healthy Participants
Interventions: BMS-986256, Mycophenolate Mofetil; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Health Volunteers
Interventions: CTP-543; Drug
Lead sponsor: Concert Pharmaceuticals; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 16 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: COVID-19
Interventions: albuterol sulfate (MDI), albuterol sulfate (nebulizer); Drug
Lead sponsor: Theravance Biopharma; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Healthy Volunteers
Interventions: AZD9833, Midazolam, Omeprazole, Dabigatran Etexilate, Celecoxib; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 50 Years to 70 Years · Female only
Enrollment: 59 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 2
States / cities: Long Beach, California • Berlin, New Jersey

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: FF 400 mcg, UMEC 500 mcg, UMEC 250 mcg, VI 100 mcg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Visual Acuity
Interventions: Dailies Total 1® Multifocal Contact Lenses, Air Optix® Multifocal Contact Lenses Plus HydraGlyde®; Device
Lead sponsor: Johnson & Johnson Vision Care, Inc.; Industry
Eligibility: 40 Years to 70 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 3
States / cities: Roswell, Georgia • Granville, Ohio • Memphis, Tennessee

Conditions: Healthy Participants
Interventions: ACP-196, Calcium carbonate, Omeprazole, Rifampin; Drug
Lead sponsor: Acerta Pharma BV; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: cMET-dysregulated Advanced Solid Tumors
Interventions: INC280, digoxin, rosuvastatin; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 2
States / cities: Atlanta, Georgia • Lebanon, New Hampshire

Conditions: Post Menopausal Osteoporosis
Interventions: Risedronate, ibandronate [Bonviva/Boniva]; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 55 Years to 80 Years · Female only
Enrollment: 356 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 48
States / cities: Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 42 more

Conditions: Spinal Cord Injuries, Peripheral Nerve Injuries
Interventions: MyndMove Short Term Therapy, Conventional Short Term Therapy, MyndMove Long Term Therapy; Device · Other
Lead sponsor: University of Miami; Other
Eligibility: 18 Years to 70 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Uterine Fibroids
Interventions: MR Elastography; Radiation
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 134 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Opioid Use Disorder
Interventions: Morphine, AZD4041, Placebo; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Postbariatric Hypoglycemia
Interventions: exendin 9-39, Placebo; Drug · Other
Lead sponsor: Eiger BioPharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 5
States / cities: Palo Alto, California • Aurora, Colorado • Baltimore, Maryland + 2 more

Conditions: Dose Finding Study
Interventions: TAK-828, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 2
States / cities: Baltimore, Maryland • Austin, Texas

Conditions: Healthy
Interventions: Telotristat etiprate; Drug
Lead sponsor: Lexicon Pharmaceuticals; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2014
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Healthy, PK Drug-drug Interaction Study
Interventions: Hydrocodone Bitartrate, Hydrocodone Bitartrate + Doxapram Hydrochloride; Drug
Lead sponsor: Quivive Pharma, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Stroke
Interventions: Music Playing Task; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 89 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Compare the Pharmacokinetic of K-877 Controlled Release (CR) and Immediate Release (IR) Tablets in Healthy Adults.

Motor Attention Training for Attention Deficit Hyperactivity Disorder (ADHD)

Spermatogonial Differentiation Via Testicular Organoid

A Phase I Study To Estimate The Effect Of Ketoconazole And Omeprazole On The Pharmacokinetics Of Dimebon In Healthy Subjects Who Are Normal Or Poor CYP2D6 Metabolizers

Building Equitable Linkages With Interprofessional Education Valuing Everyone

Isocaloric Navy-Bean Substitution in Adults With MASLD

A Study to Evaluate the Adherence of 2 Strengths of Newly Manufactured Samples and Aged Samples of a New Formulation (JNJ-35685-AAA-G016 and JNJ-35685-AAA-G021) of Fentanyl Transdermal System Compared With Duragesic Fentanyl Transdermal Patch in Healthy Participants

Effects of BMS-986256 at Steady State on the Single Dose Pharmacokinetics of Mycophenolate Mofetil

Study of the Effect of Food on the Bioavailability of the To-Be-Marketed Formulation of CTP-543 in Healthy Volunteers

Comparison of Viral Particle Dispersion Following Administration of an MDI or Nebulizer in Subjects With COVID-19

Study to Assess the Effect of Co-Administration of AZD9833 on the Pharmacokinetics of Midazolam, of Omeprazole, of Celecoxib and of Dabigatran Etexilate in Healthy Postmenopausal Female Volunteers

Pharmacokinetic Study in Healthy Volunteers to Characterise the Exposure of Fluticasone Furoate (FF), Vilanterol (VI) and Umeclidinium (UMEC) at Two Different Doses

Comparison of Two Silicone Hydrogel Multifocal Contact Lenses

A Study to Evaluate the One-way Interaction of Calcium Carbonate, Omeprazole, or Rifampin on ACP-196

A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors

A Study Comparing Monthly Boniva (Ibandronate) and Weekly Risedronate in Women With Post-Menopausal Osteoporosis.

Upper Extremity Functional Electrical Stimulation (FES) for Restoration of Upper Extremity Function After Spinal Cord Injury (SCI)

Magnetic Resonance Elastography (MRE) of Uterine Fibroids

A Study to Assess the Effect of AZD4041 on Respiratory Drive in Recreational Opioid Users.

Safety and Efficacy of Exendin 9-39 in Patients With Postbariatric Hypoglycemia

Safety, Tolerability and Pharmacokinetics of Escalating Single Doses of TAK-828 in Healthy Participants

An Open-Label Food Effect Study of Telotristat Etiprate

Study to Investigate the Safety, Tolerability and Pharmacokinetics of QEV-817 Oral Suspension

Optimizing Music-Based Interventions for Stroke